Clinical Trial Update: A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3 [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating anlotinib in patients with Gastroenteropancreatic Neuroendocrine Tumor G3 is ongoing or not yet reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Gastroenteropancreatic Neuroendocrine Tumor G3 | Phase 2 | Status: UNKNOWN